{"title":"U.S. Women Need the Dapivirine Ring, Too: FDA as Structural Barrier to HIV Prevention for Women.","authors":"Erica L Gollub, Raven Vaughan","doi":"10.1521/aeap.2022.34.4.311","DOIUrl":null,"url":null,"abstract":"<p><p>The dapivirine monthly vaginal ring-a discreet, anti-HIV microbicide created specifically for women-has received a positive scientific opinion by the European Medicines Agency and is included in the WHO HIV prevention guidelines. It has received regulatory approvals in several countries in southern and eastern Africa. During the review of the New Drug Application that was submitted in December 2020, FDA advised the developer, International Partnership for Microbicides, that it was unlikely to be approved in the United States; the application has since been withdrawn. This commentary will present the case for FDA approval for the dapivirine ring. Advocacy is urgently needed to protect U.S. women's access to user-controlled HIV prevention technologies, consistent with both global regulatory decisions to date and with a reproductive justice framework. Women continue to need the fullest range of HIV prevention methods to integrate into their lives in the most practical and effective way possible.</p>","PeriodicalId":47801,"journal":{"name":"Aids Education and Prevention","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aids Education and Prevention","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1521/aeap.2022.34.4.311","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"EDUCATION & EDUCATIONAL RESEARCH","Score":null,"Total":0}
引用次数: 2
Abstract
The dapivirine monthly vaginal ring-a discreet, anti-HIV microbicide created specifically for women-has received a positive scientific opinion by the European Medicines Agency and is included in the WHO HIV prevention guidelines. It has received regulatory approvals in several countries in southern and eastern Africa. During the review of the New Drug Application that was submitted in December 2020, FDA advised the developer, International Partnership for Microbicides, that it was unlikely to be approved in the United States; the application has since been withdrawn. This commentary will present the case for FDA approval for the dapivirine ring. Advocacy is urgently needed to protect U.S. women's access to user-controlled HIV prevention technologies, consistent with both global regulatory decisions to date and with a reproductive justice framework. Women continue to need the fullest range of HIV prevention methods to integrate into their lives in the most practical and effective way possible.
达匹维林阴道环——一种专门为女性设计的谨慎的抗艾滋病毒杀菌剂——已经得到了欧洲药品管理局的积极科学评价,并被列入世界卫生组织艾滋病毒预防指南。它已经在非洲南部和东部的几个国家获得了监管部门的批准。在对2020年12月提交的新药申请进行审查期间,FDA建议杀菌剂国际合作伙伴组织(International Partnership for micro杀剂),该药物不太可能在美国获得批准;该申请已被撤回。本评论将介绍FDA批准达匹维林环的案例。迫切需要宣传,以保护美国妇女获得用户控制的艾滋病毒预防技术,这既符合迄今为止的全球监管决定,也符合生殖司法框架。妇女仍然需要最全面的艾滋病毒预防方法,以便以最实际和最有效的方式融入她们的生活。
期刊介绍:
Presenting state-of-the-art research and information, AIDS Education and Prevention is a vital addition to the library collections of medical schools, hospitals, and other institutions and organizations with HIV/AIDS research programs. The journal integrates public health, psychosocial, sociocultural, and public policy perspectives on issues of key concern nationally and globally.